Boston Scientific device outperforms warfarin in atrial fibrillation study

05/10/2013 | MassDevice.com (Boston)

Boston Scientific's Watchman device proved more effective and safer in treating patients with atrial fibrillation than the anti-coagulant drug warfarin, according to a 707-participant study. The study showed Watchman was superior to warfarin "for the combined endpoint of all stroke, cardiovascular or unexplained death and systemic embolism," the company said in a release.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD